Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis

pharmafile | September 3, 2019 | News story | Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma 

New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment of relapsing forms of multiple sclerosis (RMS).

The trials, spanning 350 sites across 37 countries and comprising 1,882 patients between 18 and 55, revealed that the monthly subcutaneous 20mg formulation of ofatumumab met its primary endpoint to reduce the annualised relapse rate (ARR) compared to the daily oral 14mg Aubagio therapy, showing a “highly significant and clinically meaningful reduction in the number of confirmed relapses”.

Ofatumumab also met its secondary endpoints, effectively delaying time to confirmed disability progression in patients.  

“This data signifies a possible turning point for ofatumumab and provides support for our belief that it has the potential, if approved, to become the first subcutaneous B-cell therapy for relapsing MS that can be self-administered by patients at home,” remarked Dr Jan van de Winkel, Chief Executive Officer of Genmab. “We look forward to feedback from regulatory authorities and to this exciting next phase in ofatumumab’s development.”

Novartis confirmed its plans to submit these data in support of regulatory applications by the end of this year.

Matt Fellows

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …

Latest content